A comparison of these cases with high-risk–variant CHEK2-associated BCs revealed a numerically but not statistically significantly later BC onset in CHEK2 p.Ile157Thr carriers than in CHEK2 high-risk–variant carriers (58 vs 48.5 years, P = .07, Mann-Whitney U test; Supplementary Figure 5A, available online). The gene discussed is CHEK2; the disease is breast cancer.